

**Review Committee on
Regulation of Pharmaceutical Products in Hong Kong**

Membership

Chairman : Ms Sandra LEE
Permanent Secretary for Health

**Vice
Chairman** : Dr LAM Ping-yan
Director of Health

**Official
Members** : Dr Gloria TAM
Deputy Director of Health

Mr Anthony CHAN
Chief Pharmacist, Department of Health

Dr CHEUNG Wai Lun
Director (Cluster Services), Hospital
Authority

Ms Anna LEE
Chief Pharmacist, Hospital Authority

**Non-Official
Members** : Ms Sabrina CHAN
Executive Director,
Hong Kong Association of the
Pharmaceutical Industry

Ms Iris CHANG
President,
The Practising Pharmacists Association of
Hong Kong

Ms Celine CHENG
President,
The Hong Kong Pharmaceutical
Manufacturers Association Ltd.

Ms Sandra CHOW
Chairperson,
Care for your Heart – Cardiac Patients
Mutual Support Association
(up to late December 2009)

Mr William CHUI
Vice President,
The Society of Hospital Pharmacists of Hong
Kong

Mr Benjamin KWONG
President,
The Pharmaceutical Society of Hong Kong

Dr Alan LAU
Chairman,
Hong Kong Private Hospitals Association

Mr Andy LAU
Chairman,
Alliance for Renal Patients Mutual Help
Association

Ms Connie LAU
Chief Executive,
Consumer Council

Mr LAU Oi Kwok
Chairman,
Hong Kong General Chamber of Pharmacy
Ltd.

Professor Kenneth LEE
Professor, School of Pharmacy
The Chinese University of Hong Kong

Dr TSE Hung Hing
President,
Hong Kong Medical Association

Ms Tina YAP
Chairman,
The Pharmaceutical Distributors Association
of Hong Kong

Dr YEUNG Chiu Fat
President,
Hong Kong Doctors Union

Secretary : Ms Shirley LAM,
Principal Assistant Secretary for Health,
Food and Health Bureau

Terms of Reference

1. To comprehensively review the existing regime for the regulation of pharmaceutical products in Hong Kong with a view to ensuring patient safety, protecting public health and enhancing the standard and performance of the pharmacy profession and the pharmaceutical industry.
2. To make proposals to enhance the control of the supply chain of pharmaceutical products, covering manufacturers, importers, wholesalers and retailers.
3. To make proposals to enhance the control of pharmaceutical products, including –
 - (a) reviewing the Good Manufacturing Practice (GMP) Scheme for safety and quality assurance;

- (b) strengthening the enforcement mechanism, including effective penalty system, for GMP compliance; and
 - (c) tightening the pre-market and post-market control of pharmaceutical products.
4. To recommend measures to enhance the standard and performance of the pharmaceutical industry, including strengthening the governance and internal audit system of manufacturers, and the establishment of a robust microbiological vigilance system in the manufacturing process.
 5. To make proposals for legislative amendments, if required, in support of the enhanced regulatory framework.
 6. To review the mechanism for the procurement and supply of pharmaceutical products in the Hospital Authority and the Department of Health, including post-delivery verification, storage and auditing of the products.
 7. To propose a code of practice to private hospitals and private medical practitioners on procurement and supply of pharmaceutical products.